We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns on Direct-to-Clinic Promotion of Illicit Cancer Drugs
FDA Warns on Direct-to-Clinic Promotion of Illicit Cancer Drugs
January 16, 2012
FDA is advising healthcare providers to be on the lookout for fake cancer drugs, after the agency learned of U.S. clinics receiving promotions for unapproved injectables from third-party sources.